PSYBIO THERAPEUTICS CORP.

Press Releases PsyBio Therapeutics Corp.

Equities

PSYB.H

CA6936971044

Delayed Toronto S.E. Other stock markets 09:54:13 29/03/2024 am IST			5-day change	1st Jan Change
0.01 ^CAD	-.--%		-.--%	-.--%

2021	PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs	CI
2021	PsyBio Therapeutics : Files Novel Psychedelic Compositions and Methods of Treatment Patent With USPTO	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PsyBio Therapeutics : Reports Second Quarter 2021 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones	31/21/31	AQ
PsyBio Therapeutics : Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs	16/21/16	AQ
PsyBio Therapeutics : Adds NMDA Receptor Antagonists and Associated Analogues into its Intellectual Property Portfolio	04/21/04	AQ
PsyBio Therapeutics : CEO and CMO to Participate in Fireside Chat at LifeSci Partners Summer Symposium	20/21/20	AQ
PsyBio Therapeutics : Announces Uplisting to OTCQB Venture Market	14/21/14	AQ
PsyBio Therapeutics : Augments Intellectual Property Portfolio with Filing of Next Novel Psychedelic Compositions and Methods of Treatment Patent	13/21/13	AQ
PsyBio Therapeutics : Announces TSXV Approval of Share Buyback Program	28/21/28	AQ
PsyBio Therapeutics : Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie	22/21/22	AQ
PsyBio Therapeutics : Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors	21/21/21	AQ
PsyBio Therapeutics : Retains KCSA Strategic Communications for Investor Relations Services	09/21/09	AQ
PsyBio Therapeutics : Strengthens its Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer	05/21/05	AQ
PsyBio Therapeutics Announces Retention of Market Maker	04/21/04	GL
PSYO THER : PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Global Contract Research, Development and Manufacturing Organization	02/21/02	AQ
PsyBio Announces Second Quarter Financial Results of Leo Acquisition Corp.	02/21/02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW